The DOI matches its Crossref record.
Efficacy and Safety of Levetiracetam in Children with Partial Seizures: An Open‐label Trial
Abstract
Summary: Purpose: To assess the efficacy and safety of levetiracetam (LEV) as adjunctive therapy in children with treatment‐resistant partial‐onset seizures. Methods: Children (aged 6–12 years) with treatment‐resistant partial‐onset seizures receiving one standard antiepileptic drug (AED) were eligible. After a 4‐week baseline period, children received LEV in a 6‐week titration phase (target dose, 40 mg/kg/day) followed by an 8‐week evaluation phase. Seizure frequency during the evaluation period with individualized LEV doses (20–40 mg/kg/day) were compared with the 4‐week baseline seizure frequency. Plasma concentrations of LEV and other AEDs were determined to evaluate potential drug interactions. Results: Twenty‐four subjects enrolled and received LEV; 23 entered the evaluation phase, and 22 completed the evaluation phase. Compared with their baseline seizure frequency, 12 (52%) of 23 subjects entering the evaluation phase had their seizure frequency decrease by >50%. Two subjects remained seizure free during the entire evaluation period. LEV did not significantly affect plasma concentrations of any concomitant AED during this study, and no alteration of mean clinical laboratory values was observed. The most commonly reported adverse events were headache, infection, anorexia, and somnolence. Conclusions: This open‐label study of adjunctive LEV therapy (at 20–40 mg/kg/day) suggests that LEV is effective, safe, and well tolerated in children ages 6–12 years with treatment‐resistant partial‐onset seizures. A randomized, placebo‐controlled, double‐blind trial of LEV adjunctive therapy in children with treatment‐resistant partial‐onset seizures is needed and ongoing to confirm these open‐label findings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Guerrini, R. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68182-8 · Cited by 848
French, J. A., Kanner, A. M., Bautista, J., Abou-Khalil, B., Browne, T., Harden, C. L., Theodore, W. H., Bazil, C., Stern, J., Schachter, S. C., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000123693.82339.fc · Cited by 654
Self-citationClinical Pharmacokinetics of Levetiracetam
Patsalos, P. N. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443110-00002 · Cited by 473
Drug interactions involving the new second- and third-generation antiepileptic drugs
Johannessen Landmark, C., & Patsalos, P. N. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.136 · Cited by 321
Cognitive side effects of antiepileptic drugs in children
Loring, D. W., & Meador, K. J. (2004) · Neurology · doi:10.1212/01.wnl.0000115653.82763.07 · Cited by 265
Metadata
- Authors
- Glauser, T. A., Pellock, J. M., Bebin, E. M., Fountain, N. B., Ritter, F. J., Jensen, C. M., & Shields, W. D.
- Venue
- Epilepsia
- Publisher
- Wiley
- Published
- 2002-05
- Volume
- 43
- Issue
- 5
- Pages
- 518-524
- ISSN
- 0013-9580 (ISSN-L)
- 1528-1167
- OpenAlex
- W2069166395
- Cited by
- 160
- References
- 0
- FWCI
- 9.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and Safety of Levetiracetam in Children with Partial Seizures: An Open‐label Trial. https://app.cochat.ai/papers/10.1046/j.1528-1157.2002.13101.x
- The paper
- Glauser, T. A., Pellock, J. M., Bebin, E. M., Fountain, N. B., Ritter, F. J., Jensen, C. M., & Shields, W. D. (2002). Efficacy and Safety of Levetiracetam in Children with Partial Seizures: An Open‐label Trial. Epilepsia. https://doi.org/10.1046/j.1528-1157.2002.13101.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.